Medical News

Health Information / Medical News

MEDICAL NEWS

Medical News

医药资讯

Updates on Japanese weight-loss medications, GLP-1 therapies, new drug development, and global pharmaceutical trends for users preparing for consultation.

GLP-1 MedicationsJapan MedicineDrug PipelineMarket Trends
Rx

Recommended Reading Order

Start with available medications in Japan, then continue with new drug development and market trends.

01 Japan GLP-1 StatusA practical overview of GLP-1 and obesity medications used in Japan, including Semaglutide, Tirzepatide, and local treatment context.
02 Drug DevelopmentA clear summary of Retatrutide, its triple-agonist mechanism, clinical progress, approval status, and safety considerations.
03 Pipeline ReviewA pipeline overview covering Tirzepatide, Retatrutide, Orforglipron, and future obesity therapy directions.
04 Market LandscapeA comparison of the two leading companies shaping the next decade of obesity and metabolic treatment.

Medical News Articles

These articles are for educational reading and pre-consultation reference only. They do not replace diagnosis, prescriptions, or individualized medical advice.

01
Japan GLP-1 Status

Which GLP-1 and Weight Loss Medications Are Available in Japan?

A practical overview of GLP-1 and obesity medications used in Japan, including Semaglutide, Tirzepatide, and local treatment context.

Read article
02
Drug Development

Retatrutide Update: How Close Is It to Approval?

A clear summary of Retatrutide, its triple-agonist mechanism, clinical progress, approval status, and safety considerations.

Read article
03
Pipeline Review

Exploring Eli Lilly’s Future Obesity Drug Pipeline

A pipeline overview covering Tirzepatide, Retatrutide, Orforglipron, and future obesity therapy directions.

Read article
04
Market Landscape

Novo Nordisk vs Eli Lilly: Who Will Lead the Future of Obesity Treatment?

A comparison of the two leading companies shaping the next decade of obesity and metabolic treatment.

Read article
05

Retatrutide vs Tirzepatide vs Semaglutide: What Is the Difference?

Compare GLP-1, GIP, and glucagon receptor mechanisms, and understand why next-generation obesity drugs are being closely watched.

Read article
11
Industry Trends

Four Keywords in the 2026 Global Pharma Market: Oncology, Immunology, Diabetes and Obesity

These therapeutic areas are shaping future growth and patient demand.

Read article
12
Prescription Process

Why Japanese Prescription Medicines Cannot Be Bought Directly

Understanding Japan’s prescription process reduces compliance risk and user misunderstanding.

Read article
13
Regenerative Medicine

Why Is Regenerative Medicine in Japan Getting Attention?

Japan’s iPS cell and regenerative medicine progress attracts attention, but users need to understand both promise and limits.

Read article
14
Cognitive Health

New Alzheimer’s Drug Era: Who Should Understand Anti-Amyloid Treatment?

New drugs such as Leqembi and Kisunla mark a new stage, but suitability is complex.

Read article
15
AI Biopharma

How Is AI Changing Drug Development?

AI is entering target discovery, molecule design, clinical trials, and real-world evidence.

Read article

Reading Note

Medical news content may change as Japanese regulations, clinical trials, and global market conditions evolve. Suitability, dosage, and risk decisions should always be confirmed by qualified medical professionals and local regulations.

Latest Articles

Medical News

Why Can’t Prescription Medicines Be Purchased Directly in Japan?

Many international customers ask a simple question when they learn about Japanese prescription medicines: if I alre

Read more
Medical News

Japanese Pharmacy vs Drugstore: What Should Foreign Visitors Know?

Many visitors to Japan enjoy shopping at drugstores. They sell cold medicines, eye drops, stomach remedies, pain re

Read more
twl-footer-grid{width:100%;display:grid;grid-template-columns:1.9fr .85fr .85fr 1.25fr 1.55fr;column-gap:52px;align-items:start} .twl-footer-brand{display:flex;align-items:center;gap:18px;min-width:0} .twl-footer-logo{width:86px;height:86px;object-fit:cover;border-radius:4px;flex:0 0 auto} .twl-footer-name{font-size:28px;line-height:1.12;color:#122d24;font-weight:800;white-space:normal} .twl-footer-col h3{margin:0 0 20px;color:#122d24;font-size:20px;line-height:1.3;font-weight:800} .twl-footer-col p,.twl-footer-col a{display:block;margin:0 0 13px;color:#53645f;font-size:17px;line-height:1.45;text-decoration:none} .twl-footer-contact p{white-space:nowrap} .twl-footer-qrs{display:flex;gap:20px;justify-content:flex-start;align-items:flex-start} .twl-qr-item{text-align:center;color:#53645f;font-size:15px;line-height:1.3} .twl-qr-item img{width:92px;height:92px;object-fit:cover;display:block;border:1px solid #d7ebe5;border-radius:8px;padding:8px;background:#fff;margin:0 auto 9px;cursor:zoom-in} .twl-footer-bottom{margin-top:42px;padding:22px 0 0;border-top:1px solid #eef3f1;display:flex;justify-content:space-between;gap:24px;align-items:center;color:#7a8783;font-size:15px;line-height:1.5} .twl-footer-bottom a{color:#53645f;text-decoration:none;margin-left:28px} .twl-qr-lightbox{position:fixed;inset:0;background:rgba(13,31,27,.72);z-index:999999;display:none;align-items:center;justify-content:center;padding:24px} .twl-qr-lightbox.is-open{display:flex} .twl-qr-lightbox-card{background:#fff;border-radius:14px;padding:22px 22px 18px;max-width:min(92vw,520px);box-shadow:0 24px 70px rgba(0,0,0,.28);text-align:center;position:relative} .twl-qr-lightbox-card img{display:block;width:min(76vw,420px)!important;height:auto!important;max-height:70vh!important;object-fit:contain!important;margin:0 auto 12px!important;border:0!important;padding:0!important} .twl-qr-lightbox-close{position:absolute;right:10px;top:8px;border:0;background:transparent;font-size:30px;line-height:1;color:#53645f;cursor:pointer} .twl-qr-lightbox-title{font-size:18px;font-weight:800;color:#122d24;margin-top:6px} @media(max-width:1100px){.twl-custom-footer{max-width:calc(100% - 40px)}.twl-footer-grid{grid-template-columns:1fr 1fr;row-gap:30px}.twl-footer-qrs{grid-column:1/-1}} @media(max-width:680px){.twl-custom-footer{padding:30px 0 28px;margin-top:36px}.twl-footer-grid{grid-template-columns:1fr;gap:24px}.twl-footer-qrs{flex-wrap:wrap}.twl-footer-contact p{white-space:normal}.twl-footer-bottom{flex-direction:column;align-items:flex-start}.twl-footer-bottom a{margin-left:0;margin-right:22px}}
Scroll to Top